3Piegas LS;Flather M;Pogue J.The Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry in patients with unstable angina,1999(84).
4Ferreiros ER;Kevorkian R;Fuselli JJ.First national survey on management strategies in non ST-elevation acute ischaemic syndromes in Argentina. Results of the STRATEG-SIA study[J],2002.
6Cohen M;Demers C;Gurfinkel EP.A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group,1997.
7Spencer FA;Santopinto JJ;Gore JM.Impact of aspirin on presentation and hospital outcomes in patients with acute coronary syndromes (The Global Registry of Acute Coronary Events [GRACE])[J],2002(90).
8Chang WC;Harrington RA;Simoons ML.Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction?Insights from the PURSUIT Trial[J],2002(14).
9Gurfinkel EP;Manos EJ;Mejail RI.Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia[J],1995.
10The SYNERGY Executive Committee.Superior Yield of the New strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa inhibitors. The SYNERGY trial:,2002.
